1. Home
  2. JSPR vs SNAL Comparison

JSPR vs SNAL Comparison

Compare JSPR & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

SELL

Current Price

$14.35

Market Cap

26.3M

Sector

Health Care

ML Signal

SELL

Logo Snail Inc.

SNAL

Snail Inc.

SELL

Current Price

$2.14

Market Cap

21.2M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
JSPR
SNAL
Founded
2018
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
26.3M
21.2M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
JSPR
SNAL
Price
$14.35
$2.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 321.1K
124.1K
Earning Date
11-27-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
19.22
★ 120.00
EPS
★ N/A
N/A
Revenue
N/A
★ $81,225,622.00
Revenue This Year
N/A
$22.50
Revenue Next Year
N/A
$9.55
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.32
$0.59
52 Week High
$17.03
$21.60

Technical Indicators

Market Signals
Indicator
JSPR
SNAL
Relative Strength Index (RSI) 80.68 45.40
Support Level $0.64 $1.92
Resistance Level $17.03 $2.63
Average True Range (ATR) 1.05 0.27
MACD 1.15 0.04
Stochastic Oscillator 79.63 23.36

Price Performance

Historical Comparison
JSPR
SNAL

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

About SNAL Snail Inc.

Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.

Share on Social Networks: